Phase 4Completed
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
A Two-part, Multicenter, Dose-titration Study Evaluating the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Oxybutynin Chloride 10% Gel for the Treatment of Detrusor Overactivity Associated With a Neurological Condition in Pediatric Patients
- Sponsor
- AbbVie (Industry)
- Enrollment
- 52 enrolled
- Conditions
- Overactive Detrusor; Neurogenic Bladder
- Interventions
- Oxybutynin; Placebo
- Ages
- children
- Registry
- NCT01192568
Full record on ClinicalTrials.gov
From the registry
This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a potential dose titration. At this time their dose may be adjusted up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the individual response and tolerability. The total treatment time is 14 weeks and total time on the study is 16 weeks.
Primary outcomes
- Change From Baseline in Percent of Catheterizations Without a Leaking Accident at Week 6
History
Results first posted
Last registry update
Study completion
Primary completion
Started
Registered